Research News
Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
June 26th, 2014
In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.
Read More
Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
June 26th, 2014
In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.
Read More
Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
June 26th, 2014
In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.
Read More
Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
June 26th, 2014
In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.
Read More
Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
June 26th, 2014
In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.
Read More
Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
June 26th, 2014
In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.
Read More
New treatment option for young women with hormone-sensitive breast cancer
May 31st, 2014
A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
Read More
New treatment option for young women with hormone-sensitive breast cancer
May 31st, 2014
A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
Read More
New treatment option for young women with hormone-sensitive breast cancer
May 31st, 2014
A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
Read More
Sorafenib Improves Progression-Free Survival in Some Patients with Metastatic Thyroid Cancer
May 26th, 2014
Results from an international phase III trial show that sorafenib (Nexavar®) may benefit patients with locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine. Patients who were treated with sorafenib lived longer without their cancers getting worse than patients who received a placebo.
Read More
Learn More